Kyverna’s deal pair tackles two hurdles for CAR Ts outside cancer

Through a pair of deals, Kyverna is taking on two major challenges for bringing CAR T cells outside of cancer: toxicity and accessibility.

Turning CAR T cells into general-purpose tools will require companies to break through safety and commercial barriers that still limit their use in cancer. The critical advance is for the risks of neurotoxicity and cytokine release syndrome to be mitigated, and for the technology to come off-the-shelf...